Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ethyl Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Acetate SCHEMBL28330869 | 0.97 | ALDH1A1 (0.70) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL7636617 | 0.95 | ALDH1A1 (0.67) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL7465979 | 0.95 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL2122965 | 0.95 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL8008056 | 0.95 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL7341346 | 0.95 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL7428573 | 0.95 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL10004052 | 0.95 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL17007297 | 0.95 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL3113295 | 0.95 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109674747-B | Preparation method for reducing toxic and side effects of girald daphne bark injection | 甘肃兰药药业有限公司 | 2022-03-08 | — | — | CN | claimed |
| CN-116650580-B | Daphne giraldii Nitsche product and preparation method and application thereof | 秦皇岛市山海关药业有限责任公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-116650580-A | Daphne giraldii Nitsche product and preparation method and application thereof | 秦皇岛市山海关药业有限责任公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-109674747-B | Preparation method for reducing toxic and side effects of girald daphne bark injection | 甘肃兰药药业有限公司 | 2022-03-08 | — | — | CN | disclosed |
| US-8530477-B2 | Tropane urea derivatives, preparation thereof and therapeutic application thereof as modulators of the activity of 11betaHSD1 | SANOFI (FR) | 2013-09-10 | — | — | US | disclosed |
| US-20110294809-A1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | SANOFI-AVENTIS (FR) | 2011-12-01 | — | — | US | disclosed |
| CN-1129476-C | Catalyst for producing lower fatty acid ester, method for producing the catalyst, and method for producing lower fatty acid ester using the catalyst | SHOWA DENKO KK (JP) | 2003-12-03 | — | — | CN | disclosed |
| EP-0863136-B1 | Derivatives of azetidine and pyrrolidine | AKZO NOBEL NV (NL) | 2003-09-24 | — | — | EP | disclosed |
| US-6610694-B1 | Suppressing histamine and/or eosinophil chemotaxis; treating allergic diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-26 | — | — | US | disclosed |
| US-6403573-B1 | BICYCLIC-CARBO OR HETERO OXY OR BICYCLIC CARBO OR HETERO SULFIDE CONTAINING PYRROLIDINE/AZETIDINE DERIVATIVES USED AS ANTIDEPRESSANT OR PREVENTING SEROTONIN-RELATED DISEASES | AKZO NOBEL N.V. (NL) | 2002-06-11 | — | — | US | disclosed |
| US-4921982-A | 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acids useful as intermediates for 5-HT3 antagonists | ELI LILLY AND COMPANY (US) | 1990-05-01 | — | — | US | disclosed |
| US-4880806-A | BACTERICIDES | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1989-11-14 | — | — | US | disclosed |
| US-4855292-A | ANTIMICROBIAL AGENTS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1989-08-08 | — | — | US | disclosed |
| EP-0307172-A2 | Improvements in or relating to specific 5-HT3 antagonists | ELI LILLY AND COMPANY (US) | 1989-03-15 | — | — | EP | disclosed |
| US-4480115-A | Direct hydrogenation of carboxylic acids to alcohol and esters | CELANESE CORPORATION (US) | 1984-10-30 | — | — | US | disclosed |
| US-4430265-A | IMMUNOSTIMULATORY ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1984-02-07 | — | — | US | disclosed |
| EP-0002677-B1 | GLUCOSAMINE-PEPTIDE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 1982-10-13 | — | — | EP | disclosed |
| EP-0002677-A1 | Glucosamine-peptide derivatives and their pharmaceutical compositions | Takeda Chemical Industries, Ltd. (JP) | 1979-07-11 | — | — | EP | disclosed |
| US-4073890-A | TREATMENT OF DIABETES AND HYPERCHOLESTEREMIA | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1978-02-14 | — | — | US | disclosed |
| US-4001199-A | Novel polypeptides useful for treating diabetes and hypercholesteremia | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294809-A1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | HSD11B1, HSD17B1, HSD17B11 | ALDH1A1 72/4885LMNA 2460/4885HSD17B10 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.